These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 34870614)
1. Building the What Comes Next Cohort for Dossa F; Metcalfe K; Sutradhar R; Little T; Eisen A; Chun K; Meschino WS; Velsher L; Ellis JL; Baxter NN CMAJ Open; 2021; 9(3):E874-E885. PubMed ID: 34870614 [TBL] [Abstract][Full Text] [Related]
2. Real-world health services utilisation and outcomes after Dossa F; Cusimano MC; Sutradhar R; Metcalfe K; Little T; Lerner-Ellis J; Eisen A; Meschino WS; Baxter NN BMJ Open; 2018 Sep; 8(9):e025317. PubMed ID: 30181190 [TBL] [Abstract][Full Text] [Related]
3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877 [TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495 [TBL] [Abstract][Full Text] [Related]
5. Genetic testing in Poland and Ukraine: should comprehensive germline testing of Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980 [TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
7. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680 [TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756 [TBL] [Abstract][Full Text] [Related]
11. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related]
13. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728 [TBL] [Abstract][Full Text] [Related]
14. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218 [TBL] [Abstract][Full Text] [Related]
15. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey. Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574 [TBL] [Abstract][Full Text] [Related]
16. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study. Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294 [TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. Ingham SL; Warwick J; Buchan I; Sahin S; O'Hara C; Moran A; Howell A; Evans DG J Med Genet; 2013 Jun; 50(6):368-72. PubMed ID: 23539753 [TBL] [Abstract][Full Text] [Related]
19. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants. Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081 [TBL] [Abstract][Full Text] [Related]
20. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]